Table 4.

Prevalence of preeclampsia and sFlt-1/PIGF ratio by maternal SARS-CoV-2 serostatus in study participants

	SARS-CoV-2 seronegative n (%) N = 32	SARS-CoV-2 seropositive n (%) N = 68	p-value	OR [95%CI]	p-valuec
Clinical Preeclampsia, (N = 100)			0.209a	1.8 [0.73 – 4.26]	0.207
No	15 (41.7)	19 (59.4)
Yes	17 (27.9)	49 (72.1)
sFlt-1/PIGF ratio, (N = 100)
Median (IQR)	58.2 (2.19–1163.7)	131.8 (0.4–2439)	0.205b	1.01 [0.99- 1.002]	0.199
Normal/Low (< 38)	13 (38.2)	21 (61.8)	0.337a	1.5 [0.64 – 3.67]	0.339
Moderate to high (≥ 38)	19 (28.8)	47 (71.2)

^aChi-square

^bWilcoxon rank sum test

^cLogistic regression

sFlt-1 soluble Fms-like tyrosine kinase 1; PIGF- Placenta growth factor